Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes

Authors:

Abstract
Summary: Extranodal marginal zone lymphoma (EMZL) is a B‐cell lymphoma arising from mucosa‐associated lymphoid tissue (MALT). The disease characteristics, clinical course and treatment vary considerably based on site of involvement. Because long‐term outcome data forEMZLare limited, we sought to describe the clinical details of a large number of patients withEMZLevaluated at the Case Comprehensive Cancer Center over a 12‐year period to identify prognostic markers including the impact of site of involvement. We identified 211 cases ofEMZLinvolving the stomach (30%), ocular adnexa (19%), lungs (16%) and intestines (9%). Initial treatment included antibiotics (18%), radiation (21%), rituximab (20%), chemotherapy (3%), rituximab + chemotherapy (7%), surgery (17%) or observation (8%). After a median follow‐up of 44·3 months (range 2·2–214·9), median progression‐free survival (PFS) was 68·2 months (95% confidence interval [CI] 54·5–111·3) and median overall survival (OS) has not been reached. Age >60 years, elevated lactate dehydrogenase level (LDH), ≥4 lymph node groups involvement, and high follicular lymphoma international prognostic index (FLIPI) were associated with inferiorPFS/OS. In summary, patients withEMZLhave excellent prognosis with medianOSin excess of 10 years. Age, elevatedLDH, advanced disease, and highFLIPIscore are associated with worse outcomes.

This publication has 47 references indexed in Scilit: